Newbridge Financial Services Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Newbridge Financial Services Group’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-300	Closed	-$2.83K	–	1325
2025 Q1	$2.83K	Hold	300	–	–	﹤0.01%	860
2024 Q4	$3.69K	Hold	300	–	–	﹤0.01%	901
2024 Q3	$4.49K	Hold	300	–	–	﹤0.01%	513
2024 Q2	$4.05K	Buy	+300	New	+$4.44K	﹤0.01%	876

Other funds holding CNCR

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Newbridge Financial Services Group's CNCR Position: Q2 2025 in Review

Newbridge Financial Services Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 300 shares — an estimated $2.83K sold.

Newbridge Financial Services Group first reported a position in CNCR in Q2 2024 and held it in 4 quarters. The position peaked at $4.49K in Q3 2024. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

Newbridge Financial Services Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
Newbridge Financial Services Group sold 300 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $2.83K.
Newbridge Financial Services Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2024 and held it in 4 quarters.
Newbridge Financial Services Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $4.49K in Q3 2024.
1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on Newbridge Financial Services Group's 13F filing for Q2 2025, filed 19 Aug 2025.